Kornimate/medical-research-clean huggingface dataset:
inferior vena cava diameter and postpartum hemorrhage

Conditions: Other Immediate Postpartum Hemorrhage, With Delivery

Summary: excessive bleeding after normal birth or cesarean section is defined as blood loss of 1000 ml or more (clinically estimated) within 24 hours after birth. it occurs in about 5% among postpartum women. postpartum hemorrhage is a leading cause of morbidity and mortality among women giving birth. postpartum hemorrhage may lead to hemorrhagic shock, renal failure, respiratory failure, need for surgical intervention, blood transfusion and hysterectomy. the cornerstone of effective treatment is rapid diagnosis and intervention in time. however, in a number of cases there is an underestimation of the volume of blood loss which may lead to delay in diagnosis and treatment. the consequences are even graver in women who delivered by a cesarean section, since unlike a normal birth in which the bleeding is external and visible, the bleeding is usually intra-abdominal, and so the delay in diagnosis may be even longer. the inferior vena cava (ivc) is a flexible blood vessel sensitive to intravascular blood volume, and its diameter varies accordingly. its diameter reflects the pressure in the right atrium, which is a measure of the cardiac preload. a number of studies have shown that the ivc diameter changes, before the variations in vital and clinical signs. recently, ivc diameter has been assessed as an assessment of intravenous fluid balance in hemodynamically stable patients with a risk of sub-volume shock. the authors concluded that the ivc measurement is a good noninvasive method, compared to catheter insertion into the right atrium, and it is available as a bedside procedure. in obstetrics the use of ivc to determine blood loos was not widely examined and there is no information regarding the use of ivc diameter as a predictor or as a detection method of postpartum bleeding. in this study the investigators aim to examine the correlation between ivc diameter and the volume of postpartum blood loss.


Eligibility criteria:
inclusion criteria: * women over the age of 18 after birth * single pregnancy * vaginal birth * term pregnancy (gestational age between week 37-42) * the newborn is appropriate for gestational age (10-90 percentile) exclusion criteria: * gestational or pre-pregnancy hypertension * heart, liver, or chronic kidney disease * women who delivered newborn with major malformation

Keywords: inferior vena cava diameter
the effect of daily exercise program on bone mineral density and cortisol level in preterm infants

Conditions: Osteopenia of Prematurity

Summary: abstract objective: this randomized controlled double-blinded experimental study was carried out to determine the effects of daily exercise program on bone mineral density and cortisol level in preterm infants with very low birth weight matched for birth weight, gestation week, and gender. study design: the study was performed with preterm infants hospitalized in the neonatal intensive care unit of a tertiary hospital. ethical committee approval, institutional permission, parental written consent were obtained. daily exercise program was implemented in preterm infants in the exercise group for 30 days, once a day, and continuing for 7-10 minutes. before and after the study the following were evaluated in preterm infants in the exercise and control group: anthropometric measurements, tibia speed of sound (sos) for bone mineral density, serum biochemical parameters and cortisol levels.

objective: this randomized controlled double-blinded experimental study was carried out to determine the effects of daily exercise program on bone mineral density and cortisol level in preterm infants with very low birth weight matched for birth weight, gestation week, and gender. study design: the study was performed with preterm infants hospitalized in the neonatal intensive care unit of a tertiary hospital. ethical committee approval, institutional permission, parental written consent were obtained. daily exercise program was implemented in preterm infants in the exercise group for 30 days, once a day, and continuing for 7-10 minutes. before and after the study the following were evaluated in preterm infants in the exercise and control group: anthropometric measurements, tibia speed of sound (sos) for bone mineral density, serum biochemical parameters and cortisol levels.

Eligibility criteria:
inclusion criteria:inclusion criteria for the infants were as follows: * postnatal age of 1-5 days, * gestational age of 28-32 weeks, * birth weight of 1,000-1,500 gr, * no diagnosis of necrotizing enterocolitis (nec), digestive system or chromosomal abnormalities, skin diseases, intrauterine growth retardation (iugr), sga, and large gestational age (lga), * no history of surgical intervention, and * no medical treatment except for appropriate vitamin supplements and antibiotic treatments. exclusion criteria: -

Keywords: preterm infants with very low birth weight (vlbw) bone mineral density cortisol exercise
shenzhen birth cohort study

Conditions: Pregnancy Complications; Gestational Diabetes; Obstetric Labor Complications; Neurodevelopmental Disorders; Childhood Obesity

Summary: the shenzhen birth cohort study was set up to investigate the effect of early life environmental exposures on short- and long-term health consequences in shenzhen, china.

shenzhen birth cohort (xinmiao project) is a scientific research/public health project under the support of shenzhen city and nanshan district, which was jointly initiated by nanshan maternity and child healthcare hospital of shenzhen and school of public health, sun yat-sen university. the project plans to recruit 10,000 participants in early pregnancy and follow up for seven years in the first stage. biological samples, questionnaires and data for child growth and development, disease and health will be collected. the study is aimed to provide evidence for dohad hypothesis and find the prevention and control measures for some childhood diseases. the core members of the research team are composed of experts from different disciplines in the field of public health, including 4 professors and 3 associate professors. with the support of an executive sponsor, the project is undertaken by the birth cohort study center. currently, the center has 3 staff form hospital (one doctor and two masters ) and 5-7 master candidates from sun yat-sen university. it is an energetic and enthusiastic team.

Eligibility criteria:
inclusion criteria: * 1. pregnant women plan to delivery and participate in child care in our hospital; 2. pregnant women plan to reside in shenzhen for at least 7 years; 3. pregnant women who show interest in the study and agree to provide informed consent; 4. gestational weeks are less than 20 weeks.those who will agree that their neonatal will be included in the study and be followed up regularly in our child health clinic until an age of 7 years. exclusion criteria: * pregnant women who have been pregnant for more than 20 weeks; refuse to participate; unable to guarantee delivery in our hospital or can't participate in child care in our hospital; mentally incapacitated and need guardians; or be unwilling to sign informed consent.
national tunisian registry of valvulopathies (nature-valve)

Conditions: Valvular Heart Disease; Valvular Stenosis; Valvular Insufficiency

Summary: the national tunisian registry of valvulopathies is an observational, prospective and multicenter study aiming to assess the epidemiological, clinical and therapeutic profile of valve disease in tunisian departments of cardiology. cardiologists from both sectors (public and private) are participating in the study, with 37 investigational centers. data will be captured electronically by dacima clinical suite, according to fda 21 cfr part 11 (food and drug administration 21 code of federal regulations part 11), hipaa (health insurance portability and accountability act) \& ich (international conference on harmonisation) requirements.


Eligibility criteria:
inclusion criteria: * patients originated from tunisia * signed informed consent * patients with at least one of the following conditions : 1. moderate to severe native mitral and / or aortic and / or tricuspid native valve disease 2. and / or a history of a previous percutaneous or surgical valve intervention 3. and / or a history of infectious endocarditis exclusion criteria: * congenital valve diseases not including bicuspid aortic valve * isolated pulmonary valvulopathies

Keywords: valvular heart aortic mitral tricuspid
effectiveness study of short course of magnesium sulfate for severe preeclamsia

Conditions: Severe Preeclampsia

Summary: magnesium sulfate is the ideal drug for seizures prophilaxis in preeclampsia. the ideal duration of this treatment after delivery is still to be established. the hypothesis is that in stable patients a shorter course of treatment is possible without prejudice to the mother.

magnesium sulfate (mgso4) is certainly the ideal drug for prevention and control of eclamptic seizures. however, there is no consensus on the appropriate duration of prophylaxis with this anticonvulsant postpartum.the objective of the present study is to compare effectiveness of 12 hours of magnesium sulfate versus 24 hours (standard treatment) in stable patients with preeclampsia.

Eligibility criteria:
inclusion criteria: * pre-eclampsia; * puerperium. exclusion criteria: * associated maternal diseases; * use of illicit drugs or other medications that might interfere with maternal hemodynamics; * contraindications to the use of magnesium sulfate: drug hypersensitivity, oliguria with urine output below 25ml/h; anuria (absent urine output), myasthenia gravis.

Keywords: severe preeclampsia magnesium sulfate anticonvulsivant
study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa

Summary: this is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. participants will be randomized 2:1 to either sonelokimab or matching placebo up to week 16.


Eligibility criteria:
inclusion criteria: 1. participants must be at least 18 years of age at the time of signing the informed consent. 2. participants who are diagnosed with hidradenitis suppurativa as determined by the investigator and have a history of signs and symptoms of hidradenitis suppurativa for at least 6 months before signing the informed consent. 3. participants who have had an inadequate response to appropriate systemic antibiotics for treatment of hidradenitis suppurativa (or demonstrated intolerance to, or had a contraindication to, systemic antibiotics for treatment of their hs), in the investigator's opinion. 4. participants who have a total an count of ≥5. 5. participants who have hs lesions present in ≥2 distinct anatomical areas, at least one of which must contain single or multiple fistulas (ie, be hurley stage ii or iii). exclusion criteria: 1. participants with a known hypersensitivity to sonelokimab or any of its excipients. 2. participants with any other active skin disease or condition that may, in the opinion of the investigator, interfere with the assessment of hs. 3. participants with underlying conditions that, in the opinion of the investigator, potentially places the participant at unacceptable risk. 4. participants with current severe or uncontrolled disease(s) that put(s) the participant at increased risk in the investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol. 5. participants with any other known autoimmune disease or any medical condition that in the opinion of the investigator would interfere with an accurate assessment of clinical symptoms of hs. 6. participants with a gastrointestinal condition including inflammatory bowel disease or diagnosis of ulcerative colitis or crohn's disease.

Keywords: hidradenitis suppurativa hidradenitis sweat gland diseases skin diseases skin diseases, bacterial suppuration anti-inflammatory agents sonelokimab nanobody apocrine gland disease
bacillus of calmette and guerin (bcg) versus gemcitabine for intravesical therapy in high risk superficial bladder cancer

Conditions: Bladder Cancer

Summary: a significant number of patients with high risk superficial bladder cancer has progression to invasive disease. no consensus exists regarding the optimal treatment to decrease the recurrence and progression rate. the aim of this research is to evaluate the safety, tolerability and efficacy of adjuvant intravesical gemcitabine vs. bcg in the treatment of high-risk superficial bladder cancer

this was a prospective, randomized study conducted from 2004 to 2006 at a single tertiary urban teaching university urological department regarding sixty-four patients with high-risk superficial bladder cancer (pt1, and/or g3 and/or cis), who were assigned to interventions (gemcitabine or bcg) by using random allocation 1:1. group a, 32 patients, were treated weekly (6 weekly instillations) with bcg dose 5 x 108 cfu and then maintenance therapy at 3-6-12-18-24-30-36 months; group b, 32 patients, received gemcitabine 2 gr/instillation on a weekly basis (6 weekly instillations), followed by maintenance therapy at 3-6-12-18-24-30-36 months.

Eligibility criteria:
inclusion criteria: * primary diagnosis of high risk superficial bladder cancer according to eau guidelines (http://www.eortc.be/tools/bladdercalculator/), * having never been treated with other intravesical chemotherapeutic agents, * and to consent to participate to the study exclusion criteria: * concomitant tumours; * urinary tract infections (uti); * altered function of the liver, kidneys and/or bone marrow; * major cardiovascular diseases; * life expectancy of less than 1 year; * intravesical chemotherapy in the previous 3 months or immunotherapy in the previous 6 months; * systemic chemotherapy and pelvic radiotherapy prior to turb, and any condition that in the judgment of the investigators would interfere with the subject's ability to provide informed consent, comply with study instructions, place the subject at increased risk, or which might confound interpretation of study results.

Keywords: bcg gemcitabine intravesical therapy superficial transitional cell carcinoma
study of fk463 in the treatment of candidemia or invasive candidiasis

Conditions: Candidiasis

Summary: the purpose of the study is to evaluate the safety and efficacy of fk463 in the treatment of patients with confirmed candidemia or invasive candidiasis.

this will be an open-label, non-comparative study of intravenous fk463. enrollment will include at least 100 patients evaluable for efficacy.

Eligibility criteria:
inclusion criteria * has candidemia or invasive candidiasis documented by typical clinical signs and symptoms and confirmed by fungal culture or histologic confirmation exclusion criteria * has abnormal liver test parameters, e.g., ast or alt \> 10 times upper limit of normal * has life expectancy judged to be less than 5 days * de novo patients who have received a systemic antifungal agent for the treatment of this episode of candidemia or invasive candidiasis for more than 48 hours prior to the first dose of fk463; or efficacy failure patients who have received =\< 5 days of prior systemic antifungal therapy for the treatment of this episode of candidemia or invasive candidiasis * require treatment with topical or systemic antifungal agents for conditions other than candidemia or invasive candidiasis

Keywords: candidemia anti-fungal
evaluation of common bean baked snack consumption on subjective satiety, energy intake and glycemic response in people with overweight and normal weight

Conditions: Overweight; Healthy

Summary: introduction: overweight and obesity are associated with an unbalanced energy intake caused by unhealthy dietary habits, including a constant consumption of energy-dense foods, saturated and trans fats, refined sugars, along with a deficient protein and dietary fiber intake. pulse consumption has been demonstrated to improve long-term body weight management. despite these benefits, in several regions, the consumption of pulses does not meet the local recommendations. consequently, pulse research has increased widely in order to provide food alternatives reformulated with pulses to promote their consumption. hypothesis: the consumption of a common bean baked snack (phaseolus vulgaris l.) and cooked beans increases satiety, reduces energy intake and produce a low glycemic response in people with overweight and normal weight. objectives: evaluate the acute effect of a common bean baked snack and cooked bean consumption on subjective satiety and energy intake in people with overweight and normal weight. material and methods: randomized crossover clinical trial, 18 subjects with normal weight and 18 subjects with overweight, 18-50 years old, consumption of 40 g of common bean baked snack, cooked beans and white bread (control). subjective satiety, energy intake and glycemic response. * intervention a: common bean baked snack. * intervention b: cooked beans. * control: white bread. additionally, the glycemic index will be determined under the international organization for standardization (iso) 26642:2010. 10 subjects with normal weight or overweight, 18-50 years old, consumption of 54 g of common bean baked snack and 25 g of anhydrous glucose. * intervention a: common bean baked snack. * control: anhydrous glucose


Eligibility criteria:
inclusion criteria: * bmi between 18.0 and 29.9 kg/m2, exclusion criteria: * pregnancy, * lactation, * established plans to lose or gain weight in the next three weeks, * surgical event or modification of diet or physical activity in the last three months, * diagnosis of diabetes, cancer, cardiovascular disease, gastrointestinal disorder, pancreatitis, kidney, liver or thyroid disease, * eating disorder, * smoking or drug use, * sensitivity for common bean consumption, * pharmacological treatment or consumption of non-prescription drugs, herbal or nutritional supplements known to modify appetite or satiety.

Keywords: functional food common bean snack cooked beans
a phase 2 trial of antisense nucleotide to pkc-alpha (ly900003, isis 3521) plus gemcitabine and carboplatin in patients with advanced, previously untreated non-small cell lung cancer.

Conditions: Carcinoma, Non-Small-Cell Lung; Pulmonary Neoplasms; Neoplasms, Lung

Summary: the purposes of this study are to determine the following: whether ly900003 plus gemcitabine and carboplatin can make your tumor smaller or disappear, and for how long. if treatment with ly900003 plus gemcitabine and carboplatin can help you live longer. the safety of ly900003 plus gemcitabine and carboplatin and any side effects that might be associated with the combination of these three drugs. how ly900003 is distributed and broken down by your body when it is given with carboplatin and gemcitabine. whether ly900003 affects the way gemcitabine and carboplatin are distributed and broken down by your body.

definition: the phase 2 study will provide important information regarding effects of ly900003 on safety and efficacy of patients treated with gemcitabine and carboplatin. ly900003 will be given at approximately 2 mg/kg/day for the first 14 days of a 21-day cycle. the dose and schedule for ly900003 administration are based on results of prior studies of ly900003 and are currently being used in other studies of ly900003. gemcitabine will be administered on days 1 and 8 at 1250 mg/m2 and carboplatin will be given on day 1 at auc 5.

Eligibility criteria:
inclusion criteria: * diagnosis of non-small-cell lung cancer. * stage iv or stage iiib disease. * ecog performance status of 0 or 1. * adequate organ function * one unidimensionally measurable lesion. exclusion criteria: * prior therapy for nsclc. * serious concomitant disorders. * untreated cns metastases. * uncontrolled, active infection. * previous ly900003/isis trial participation.

Keywords: non-small-cell lung cancer adenocarcinoma carcinoma squamous adult lung cancer
relief - resistance training for life

Conditions: Sarcopenia

Summary: sarcopenia is an age-related gradual loss of muscle mass and strength and is associated with physical disability and mortality risk. currently, the most promising remedy for preventing and treating sarcopenia is physical activity, particularly progressive resistance training. yet, the amount of resistance exercise needed to achieve optimal benefits remains largely unknown. this lack of knowledge is underpinned by the notion that aging reduces the ability to adapt to (and benefit from) resistance training, and is further complicated by a relative large degrees of between-subject heterogeneity. the primary aim of the study is to compare the effects of 10 weeks of resistance training with low- and moderate volume (one vs. three sets per exercise) on muscle mass accretion in lower and upper body extremities in young (\ 70 years of age). specifically, the study addresses the hypothesis that elderly individuals will benefit more from higher exercise volume (moderate vs. low) compared to their young counterparts. in addition, the study aims to compare the efficacy of the two volume conditions for altering other characteristics such as muscle strength and biology, including assessment of associations between individual changes in muscle mass, strength and biology (e.g. the relationship between muscle mass accretion and muscle content of rrna/rdna), and also to investigate the general health effects of the intervention.


Eligibility criteria:
inclusion criteria: * ages between 18 and 30 or \> 70 exclusion criteria: * resistance training, \> 1 session per week * endurance training, \> 3 sessions per week * unstable cardiovascular disease * illness or serious injury contradicting resistance training * serious mental illness * allergy to local anaesthesia
diffuse large b cell lymphoma of the adult: randomization between high dose chemotherapy with rituximab and chop 14-rituximab

Conditions: Lymphoma, Large-Cell, Diffuse

Summary: the aim of the protocol is to compare the outcome of patients with dlbcl stage ii bulky, iii or iv with 1 to 3 adverse prognostic factors according to the international prognostic index. patients with eligibility criteria and who gave informed consent will be randomised between chop-14- rituximab x 8 courses and high dose chemotherapy with rituximab including autologous stem cell support. the aim of the study is to compare the event free survival between the two arms and to gain insight into the prognostic significance of several biological markers gathered at the time of diagnosis/randomisation ( i.e. fcgamma r iii a genotyping, dna profile and bcl é expression).

diffuse large b cell lymphoma not previously treated

Eligibility criteria:
inclusion criteria: * age ≥ 18 et ≤ 60 and male and female * diffuse large b cell lymphoma according to who classification phénotype b cd 20 + * stage i et ii tumor bulk \> 7 cm and stage iii et iv ann arbor. * non previously treated * hiv négative * signed informed consent exclusion criteria: * age \ 60 ans * nhl not dlbcl * lymphoblastic lymphoma * burkitt's lymphoma * low grade lymphoma transformed * primary cns lymphomal * post- transplantation lymphoma * cd20 negative * ann arbor stage i or ii without tumor bulk \> 7 cm * previous treatment * hiv positive * contre-indication to rituximab use according to smpc * contre-indication to high dose chemotherapy due to organ failure not related to the lymphoma * cancer or history of cancer with the exception of in situ cancer of the cervix or non-invasive skin epithelioma * patient not able to understand the proposed treatments * refusal to sign the informed consent

Keywords: diffuse large b cell lymphoma not previously treated